Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Spoiler: There are some decreases this year, too. Here's an overview of the changing prices and what to make of them. -
The Food and Drug Administration's authorization of Florida's plan to import prescription medicines from Canada is a first. But the state still has hurdles to clear before imports could begin. -
Hospitals rely on scores of generic drugs given by injection. But these workhorses are often in short supply. Cheap prices have led to factory closures that leave the supply chain vulnerable. -
To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines. -
The National Institutes of Health has been reluctant to use its leverage as a biomedical research funder to influence drug pricing. Sen. Bernie Sanders is pressing NIH's new director to take action. -
Pharmacists struggle to find key medicines and now have to anticipate drug shortages caused by extreme weather and global instability. -
Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table. -
Many people taking Ozempic and related drugs have reported mental health concerns. Those side effects aren't in Ozempic's instructions for use. Are the problems a coincidence or related to the drug? -
The science of baby babble is surprisingly complex. And the idea that a baby exposed to two languages will be confused? Let's see what babble researchers have to say about that. -
The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.
